For the quarter ending 2025-11-30.
| Income Statement | 2025-11-30 | 2025-08-31 | ||
|---|---|---|---|---|
| Revenue | 0 | 177* | ||
| Cost of goods sold | 0 | 1* | ||
| Gross profit | 0 | 176* | ||
| Research and development | 671.34 | 2,059* | ||
| General and administrative | 902.291 | 1,086* | ||
| Total operating expenses | 1,573.631 | 3,145* | ||
| Loss from operations | -1,573.631 | -2,969* | ||
| Interest income | 0.012 | 1* | ||
| Unrealized loss on marketable securities | -22.093 | -9* | ||
| Total other income (loss) | -22.081 | -8* | ||
| Net loss before income taxes | -1,595.712 | - | ||
| Income taxes | 1.791 | - | ||
| Net loss | -1,597.503 | -2,977* | ||
| Less net loss attributable to non-controlling interest | -2.496 | -2* | ||
| Net loss attributable to lexaria shareholders | -1,595.007 | -2,975* | ||
| Foreign currency translation adjustment | -5.744 | -13* | ||
| Total comprehensive loss | -1,600.751 | -2,988 | ||
| Diluted EPS | -0.07 | -0.166 | ||
| Diluted Average Shares | 21,376,029 | 17,998,715 | ||
Lexaria Bioscience Corp. (LEXXW)
Lexaria Bioscience Corp. (LEXXW)